Lbp Am Sa Has $94.69 Million Stock Position in Stryker Corporation $SYK

Lbp Am Sa increased its position in shares of Stryker Corporation (NYSE:SYK) by 4.8% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 239,334 shares of the medical technology company’s stock after purchasing an additional 10,865 shares during the quarter. Stryker makes up approximately 1.3% of Lbp Am Sa’s holdings, making the stock its 15th biggest holding. Lbp Am Sa owned approximately 0.06% of Stryker worth $94,688,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. Goodman Advisory Group LLC acquired a new stake in Stryker in the 1st quarter valued at about $32,000. City Holding Co. increased its position in Stryker by 528.6% in the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company’s stock valued at $33,000 after acquiring an additional 74 shares in the last quarter. Ridgewood Investments LLC increased its position in Stryker by 48.4% in the 2nd quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock valued at $36,000 after acquiring an additional 30 shares in the last quarter. Ransom Advisory Ltd acquired a new stake in Stryker in the 1st quarter valued at about $37,000. Finally, Smallwood Wealth Investment Management LLC acquired a new stake in shares of Stryker during the 1st quarter worth approximately $40,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Performance

Shares of SYK opened at $369.44 on Wednesday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19. The firm’s 50 day moving average price is $384.81 and its two-hundred day moving average price is $379.11. The firm has a market cap of $141.24 billion, a P/E ratio of 48.93, a PEG ratio of 2.67 and a beta of 0.93.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating analysts’ consensus estimates of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm had revenue of $6.02 billion for the quarter, compared to analyst estimates of $5.92 billion. During the same quarter in the previous year, the firm posted $2.81 earnings per share. The business’s revenue was up 11.1% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, analysts forecast that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Stryker’s payout ratio is currently 44.50%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Rothschild Redb upgraded shares of Stryker to a “hold” rating in a research report on Thursday, September 18th. Rothschild & Co Redburn assumed coverage on shares of Stryker in a research report on Thursday, September 18th. They set a “neutral” rating and a $420.00 price target for the company. Redburn Partners set a $420.00 price target on shares of Stryker in a research report on Thursday, September 18th. Truist Financial set a $415.00 price target on shares of Stryker and gave the stock a “hold” rating in a research report on Monday, August 4th. Finally, Evercore ISI lifted their price objective on shares of Stryker from $390.00 to $415.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 8th. Fourteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $430.33.

Insiders Place Their Bets

In other news, Director Ronda E. Stryker sold 200,000 shares of the business’s stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the sale, the director owned 3,222,108 shares of the company’s stock, valued at $1,212,962,556.60. The trade was a 5.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Viju Menon sold 500 shares of the business’s stock in a transaction on Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the sale, the insider directly owned 12,511 shares in the company, valued at approximately $4,886,921.71. This represents a 3.84% decrease in their position. The disclosure for this sale can be found here. Insiders own 5.20% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.